Payment overview · 2025
General Payments
$997.13
41 reported records · 18 companies
Healthcare provider profile · identity verified
Christopher D Dobrose, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MAYFIELD, KY · NPI 1871564666
Verified facts
What the public records show
CMS Open Payments records show Christopher D Dobrose, M.D. received $997.13 in general payments during 2025 across 41 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $225.69 | 22.6% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$211.01 | 21.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $168.20 | 16.9% | 15 | 2025 |
| Reapplix Inc. | Unresolved — no canonical attribution shown | $65.29 | 6.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.56 | 6.5% | 4 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.53 | 4.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.84 | 2.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.16 | 2.4% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $23.30 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.98 | 2.0% | 1 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $19.20 | 1.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.93 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.75 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.58 | 1.6% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $15.16 | 1.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.14 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.13 | 1.4% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $13.68 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $997.13 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $211.01 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $119.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $114.19 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.99 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.22 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $77.16 | 1 | 2025 |
Source payment records
|
|||||
| 3C Patch Kit - Box Normalized: 3c patch kit box |
Device | Reapplix Inc. | $65.29 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $64.56 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.46 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $42.53 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.50 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $26.84 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 87 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
129 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 792 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 719 | 143 |
| Lisinopril | Lisinopril | 704 | 141 |
| Gabapentin | Gabapentin | 641 | 107 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 608 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 595 | 106 |
| Metoprolol Succinate | Metoprolol Succinate | 484 | 102 |
| Furosemide | Furosemide | 410 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 385 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 364 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 363 | 68 |
| Alprazolam | Alprazolam | 354 | 44 |
| Potassium Chloride | Potassium Chloride | 336 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 334 | 57 |
| Metformin Hcl | Metformin Hcl | 333 | 65 |
| Tizanidine Hcl | Tizanidine Hcl | 329 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 317 | 55 |
| Buspirone Hcl | Buspirone Hcl | 314 | 54 |
| Amitriptyline Hcl | Amitriptyline Hcl | 281 | 45 |
| Montelukast Sodium | Montelukast Sodium | 280 | 51 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 265 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 254 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 251 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 242 | 63 |
| Spironolactone | Spironolactone | 241 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 208 | 59 |
| Losartan Potassium | Losartan Potassium | 203 | 47 |
| Eliquis | Apixaban | 200 | 34 |
| Finasteride | Finasteride | 191 | 39 |
| Carvedilol | Carvedilol | 185 | 37 |
| Simvastatin | Simvastatin | 178 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 176 | 24 |
| Famotidine | Famotidine | 175 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 30 |
| Trazodone Hcl | Trazodone Hcl | 174 | 36 |
| Mirtazapine | Mirtazapine | 168 | 32 |
| Meloxicam | Meloxicam | 158 | 41 |
| Allopurinol | Allopurinol | 151 | 31 |
| Glimepiride | Glimepiride | 151 | 28 |
| Lamotrigine | Lamotrigine | 143 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 141 | 23 |
| Sucralfate | Sucralfate | 131 | 24 |
| Ozempic | Semaglutide | 129 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 127 | 24 |
| Lovastatin | Lovastatin | 126 | 21 |
| Ezetimibe | Ezetimibe | 122 | 27 |
| Promethazine Hcl | Promethazine Hcl | 122 | 17 |
| Tradjenta | Linagliptin | 117 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 116 | 21 |
| Propranolol Hcl | Propranolol Hcl | 113 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 109 | 88 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 109 | 89 |
| Ondansetron Hcl | Ondansetron Hcl | 103 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 17 |
| Nifedipine Er | Nifedipine | 99 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 99 | 14 |
| Prednisone | Prednisone | 99 | 67 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 23 |
| Baclofen | Baclofen | 93 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 15 |
| Bupropion Xl | Bupropion Hcl | 92 | 16 |
| Metolazone | Metolazone | 90 | 13 |
| Sertraline Hcl | Sertraline Hcl | 90 | 17 |
| Januvia | Sitagliptin Phosphate | 89 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 21 |
| Farxiga | Dapagliflozin Propanediol | 87 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 16 |
| Pentoxifylline | Pentoxifylline | 85 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 13 |
| Pregabalin | Pregabalin | 82 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 79 | 13 |
| Doxepin Hcl | Doxepin Hcl | 79 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 79 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 76 | 35 |
| Tramadol Hcl | Tramadol Hcl | 73 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 11 |
| Metformin Hcl Er | Metformin Hcl | 62 | 16 |
| Primidone | Primidone | 62 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 60 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 14 |
| Fenofibrate | Fenofibrate | 56 | 13 |
| Donepezil Hcl | Donepezil Hcl | 54 | suppressed |
| Diazepam | Diazepam | 53 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 53 | suppressed |
| Risperidone | Risperidone | 53 | 13 |
| Atenolol | Atenolol | 52 | 12 |
| Meclizine Hcl | Meclizine Hcl | 51 | 22 |
| Topiramate | Topiramate | 51 | 11 |
| Estradiol | Estradiol | 50 | 11 |
| Memantine Hcl | Memantine Hcl | 49 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Colchicine | Colchicine | 47 | 14 |
| Jardiance | Empagliflozin | 47 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 46 | 14 |
| Azithromycin | Azithromycin | 46 | 42 |
| Enalapril Maleate | Enalapril Maleate | 46 | suppressed |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Repatha Sureclick | Evolocumab | 46 | suppressed |
| Roflumilast | Roflumilast | 46 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 30 |
| Lorazepam | Lorazepam | 43 | 11 |
| Ondansetron Odt | Ondansetron | 42 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Repatha Syringe | Evolocumab | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Cefdinir | Cefdinir | 35 | 31 |
| Sotalol | Sotalol Hcl | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Nystatin | Nystatin | 32 | 23 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 21 |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Lactulose | Lactulose | 27 | 11 |
| Mupirocin | Mupirocin | 27 | 21 |
| Nitroglycerin | Nitroglycerin | 27 | 14 |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 16 |
| Acarbose | Acarbose | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 22 |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Griseofulvin | Griseofulvin, Microsize | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Torsemide | Torsemide | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Fluconazole | Fluconazole | 19 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 12 |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Probenecid | Probenecid | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $997.13 · 41 records | AstraZeneca Pharmaceuticals LP | 3C Patch Kit - Box, AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, INCEPTIV, Kerendia, MOUNJARO, Miro3D, NUZYRA, Natroba, OTEZLA, QULIPTA, REPATHA, REXULTI, Spinosad, Symbravo, TWIIST, Topical Oxygen Chamber for extremities, UBRELVY, VRAYLAR, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error